DSFIR Stock Analysis: DSM-Firmenich | AS
Specialty Chemicals | AS, Netherlands | Market Cap: 20.920m EUR | 12M Return: -4.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 73.5M
Qual. Beats: -4
Rev. Trend: 18.4%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
Seasonality 3.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DSM-Firmenich AG is a Swiss-headquartered company founded in 1902 and based in Kaiseraugst, providing nutrition, health, and beauty solutions across four business segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The company operates globally with a presence in eight geographic regions, including Switzerland, the Netherlands, broader Europe, the Middle East and Africa, North America, Latin America, China, and the rest of Asia.
The Perfumery & Beauty segment produces scents from natural, synthetic, and biotech-derived ingredients, while Taste, Texture & Health supplies flavors, natural extracts, sugar-reduction solutions, enzymes, hydrocolloids, cultures, colorants, and plant-based proteins to food and beverage manufacturers. Health, Nutrition & Care serves early-life nutrition, dietary supplements, pharmaceuticals, medical nutrition, and biomedical materials markets with vitamins, minerals, carotenoids, probiotics, and premix solutions. The Animal Nutrition & Health segment provides vitamins, performance solutions, and data-driven precision services to livestock and aquaculture producers.
DSM-Firmenich operates as a B2B ingredient supplier rather than a consumer-facing brand, with its products embedded in the supply chains of food, beverage, personal care, pharmaceutical, and animal feed companies. The flavors and fragrances industry in which it competes is characterized by high regulatory barriers, long-standing customer relationships, and significant investment in biotechnology and sustainable sourcing.
- Perfumery & Beauty fragrance sales rise on premium demand recovery
- Animal Nutrition margins pressured by EU vitamin pricing volatility
- Merger cost synergies accelerate post DSM-Firmenich integration completion
| Net Income: -977.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.07 > 1.0 |
| NWC/Revenue: 26.86% < 20% (prev 35.15%; Δ -8.29% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.05b > Net Income -977.0m |
| Net Debt (3.84b) to EBITDA (2.24b): 1.71 < 3 |
| Current Ratio: 1.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (260.6m) vs 12m ago -1.35% < -2% |
| Gross Margin: 38.97% > 18% (prev 30.22%; Δ 8.75% > 0.5%) |
| Asset Turnover: 38.94% > 50% (prev 37.42%; Δ 1.52% > 0%) |
| Interest Coverage Ratio: 6.71 > 6 (EBIT TTM 1.11b / Interest Expense TTM 166.0m) |
| A: 0.11 (Total Current Assets 8.89b - Total Current Liabilities 5.59b) / Total Assets 29.3b |
| B: 0.29 (Retained Earnings 8.41b / Total Assets 29.3b) |
| C: 0.04 (EBIT TTM 1.11b / Avg Total Assets 31.5b) |
| D: 1.67 (Book Value of Equity 18.2b / Total Liabilities 10.9b) |
| Altman-Z'' = 3.66 = AA |
| DSRI: 0.79 (Receivables 2.10b/2.72b, Revenue 12.3b/12.6b) |
| GMI: 0.78 (GM 30.22% / 38.97%) |
| AQI: 0.97 (AQ_t 0.55 / AQ_t-1 0.57) |
| SGI: 0.97 (Revenue 12.3b / 12.6b) |
| TATA: -0.10 (NI -977.0m - CFO 2.05b) / TA 29.3b) |
| Beneish M = -3.45 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at EUR 83.30 with a total of 1,273,256 shares traded. Over the past week, the price has changed by +1.39%, over one month by +25.41%, over three months by +39.54% and over the past year by -4.38%.
Current recommended Stop Loss: 80.30 (which is 3.6% or 1.3 ATR below the current price).
DSM-Firmenich has no consensus analysts rating.
P/E Trailing = 69.9504
P/E Forward = 24.7525
P/S = 2.3157
P/B = 1.1523
P/EG = 0.764
Revenue TTM = 12.3b EUR
EBIT TTM = 1.11b EUR
EBITDA TTM = 2.24b EUR
Long Term Debt = 3.23b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.66b EUR (from shortTermDebt, last quarter)
Debt = 5.74b EUR (from shortLongTermDebtTotal, last quarter) + Leases 463.0m
Net Debt = 3.84b EUR (calculated: Debt 5.74b - CCE 1.90b)
Enterprise Value = 24.8b EUR (20.9b + Debt 5.74b - CCE 1.90b)
Interest Coverage Ratio = 6.71 (Ebit TTM 1.11b / Interest Expense TTM 166.0m)
EV/FCF = 21.83x (Enterprise Value 24.8b / FCF TTM 1.13b)
FCF Yield = 4.58% (FCF TTM 1.13b / Enterprise Value 24.8b)
FCF Margin = 9.23% (FCF TTM 1.13b / Revenue TTM 12.3b)
Net Margin = -7.95% (Net Income TTM -977.0m / Revenue TTM 12.3b)
Gross Margin = 38.97% ((Revenue TTM 12.3b - Cost of Revenue TTM 7.50b) / Revenue TTM)
Gross Margin QoQ = 54.56% (prev 36.56%)
Tobins Q-Ratio = 0.84 (Enterprise Value 24.8b / Total Assets 29.3b)
Interest Expense / Debt = 2.89% (Interest Expense 166.0m / Debt 5.74b)
Taxrate = 26.17% (162.0m / 619.0m)
NOPAT = 822.5m (EBIT 1.11b * (1 - 26.17%))
Current Ratio = 1.59 (Total Current Assets 8.89b / Total Current Liabilities 5.59b)
Debt / Equity = 0.31 (Debt 5.74b / totalStockholderEquity, last quarter 18.2b)
Debt / EBITDA = 1.71 (Net Debt 3.84b / EBITDA 2.24b)
Debt / FCF = 3.38 (Net Debt 3.84b / FCF TTM 1.13b)
Total Stockholder Equity = 20.9b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.10% (Net Income -977.0m / Total Assets 29.3b)
RoE = -4.68% (Net Income TTM -977.0m / Total Stockholder Equity 20.9b)
RoCE = 4.62% (EBIT 1.11b / Capital Employed (Equity 20.9b + L.T.Debt 3.23b))
RoIC = 3.32% (NOPAT 822.5m / Invested Capital 24.8b)
WACC = 5.66% (E(20.9b)/V(26.7b) * Re(6.63%) + D(5.74b)/V(26.7b) * Rd(2.89%) * (1-Tc(0.26)))
Discount Rate = 6.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -53.55 | Cagr: 12.34%
[DCF] Terminal Value 77.97% ; FCFF base≈1.06b ; Y1≈1.21b ; Y5≈1.78b
[DCF] Fair Price = 93.11 (EV 26.9b - Net Debt 3.84b = Equity 23.0b / Shares 247.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -4
Revenue Correlation: 18.40 | Revenue CAGR: 1.15% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.89 | Chg30d=-1.49% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.93 | Chg30d=+0.75% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=3.50 | Chg30d=+0.43% | Revisions=+29% | GrowthEPS=-9.7% | GrowthRev=-26.5%
EPS next Year (2027-12-31): EPS=3.96 | Chg30d=+0.43% | Revisions=+29% | GrowthEPS=+13.2% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +31% (up=7, down=3)